Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS

Phytoestrogens as an Alternative to Estradiol in Reversing the Antiestrogenic Effect of Clomid on Endometrium in Ovulation Induction in Cases of Polycystic Ovarian Syndrome

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02352597

Acronym

PCOS

Enrollment

150

Registered

2015-02-02

Start date

2013-01-31

Completion date

2015-01-31

Last updated

2017-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovaries

Keywords

PCOS, Phytoestrogens, ovulation induction

Brief summary

Prospective study conducted on 150 women with polycystic ovarian syndrome (PCOS) were randomly divided into 3 groups: group I (50 women) received clomiphene citrate (CC) only 50 mg orally every 8 hours started from cycle day 3 for 5 days, group II (50 women) received 2mg estradiol valerate daily from cycle day 7 - 11 in addition to CC and group III (50 women) received phytoestrogen (20mg of cimifuga racemosa from day 1- 12) in addition to CC.

Detailed description

Prospective study conducted on 150 women with PCOS were randomly divided into 3 groups: group I (50 women) received CC only50 mg orally every 8 hours started from cycle day 3 for 5 days, group II (50 women) received 2mg estradiol valerate daily from cycle day 7 - 11 in addition to CC and group III (50 women) received phytoestrogen (20mg of cimifuga racemosa from day 1- 12) in addition to CC.

Interventions

DRUGphytoestrogen

20mg of cimifuga racemosa from day 1- 12

DRUGestradiol valerate

2mg from cycle day 7 to day 11

DRUGclomiphene citrate

50 mg orally every 8 hours started from cycle day 3 for 5 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 37 Years

Healthy volunteers

Inclusion criteria

Women with both 1ry and 2ry infertility were included. All women were between 20 and 37 years old.

Exclusion criteria

women with endocrinological abnormalities as thyroid dysfunction or abnormal prolactin levels, those with hypothalamic or pituitary dysfunctions evaluated by low gonadotropin level, other causes of infertility as tubal factor evaluated by HSG or laparoscopy, abnormal uterine cavity evaluated by sonohystrography or hysteroscopy and male factor evaluated by semen analysis. Women with ovarian cysts were also excluded from the study

Design outcomes

Primary

Measure	Time frame
endometrial thickness	day 14 of menstrual cycle

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026